On the 1st, China Chemical & Pharmaceutical (CCP) announced that Moderna Taiwan and CCP's marketing and sales subsidiary, Cenra Healthcare, have reached a collaboration agreement to jointly promote Moderna's mRNA respiratory vaccine portfolio in Taiwan. This includes Moderna's COVID-19 vaccine, Spikevax.

Under the agreement, Moderna will be responsible for the manufacturing and distribution of its mRNA respiratory vaccines, while Cenra Healthcare will manage the promotion and execution of medical education activities. The goal is to ensure that comprehensive medical information related to Moderna’s mRNA respiratory vaccines is widely disseminated across Taiwan. The initial term of the agreement runs until July 31, 2027, with no financial terms disclosed.

Joyce Lee, General Manager of Moderna Taiwan, expressed excitement about collaborating with Cenra Healthcare, a company deeply rooted in the field of infectious and respiratory diseases. She noted that Cenra’s strong market presence would help expand the reach of Moderna’s vaccines.

Moderna Taiwan is committed to advancing public health initiatives in Taiwan, especially as respiratory diseases continue to pose a global threat. This collaboration will help further education efforts related to Moderna's COVID-19 vaccine and future products.

Cenra Healthcare's General Manager, Hsu-Hui Lin, said it was an honor to collaborate with Moderna, a global leader in innovation, to contribute to Taiwan's public health. With Cenra’s market leadership and deep understanding of Taiwan’s healthcare landscape, combined with Moderna’s cutting-edge mRNA vaccines, Cenra Healthcare is fully committed to supporting Taiwan's vaccination programs and ensuring the vaccines are widely accessible through close collaboration with healthcare institutions and communities.

Resource (mandarin): 中化、莫德納簽合作協議